Aubert-Pouëssel Anne, Venier-Julienne Marie-Claire, Clavreul Anne, Sergent Michelle, Jollivet Christophe, Montero-Menei Claudia N, Garcion Emmanuel, Bibby David C, Menei Philippe, Benoit Jean-Pierre
INSERM ERIT-M 0104, Ingénierie de la Vectorisation Particulaire, IBT, 10 rue André Boquel, 49 100, Angers, France.
J Control Release. 2004 Mar 24;95(3):463-75. doi: 10.1016/j.jconrel.2003.12.012.
Glial cell line-derived neurotrophic factor (GDNF) is a protein with potent trophic actions on dopaminergic neurons, which is under investigation as a therapeutic agent for the treatment of neurodegenerative disorders, including Parkinson's disease. The aim of this work was to develop GDNF-loaded microspheres, which could be implanted by stereotaxy in the brain and could offer an alternative strategy in the treatment of Parkinson's disease. A w/o/w extraction-evaporation technique was chosen to prepare protein-loaded microspheres. An in vitro release study of the protein was required to assess the retention of integrity and the performance of the microsphere formulation with regard to sustained release. In order to assess the in vitro release profile of the GDNF-loaded microspheres, a preliminary study was performed to select an appropriate buffer for GDNF stabilization, using experimental designs. GDNF was measured by both enzyme-linked immunosorbant assay (ELISA) and radioactivity using (125)I-GDNF. The GDNF-loaded microsphere release profile was assessed in a low continuous flow system, and showed a sustained release over 56 days of biologically active GDNF at clinically relevant doses.
胶质细胞系源性神经营养因子(GDNF)是一种对多巴胺能神经元具有强大营养作用的蛋白质,目前正作为治疗包括帕金森病在内的神经退行性疾病的治疗药物进行研究。这项工作的目的是开发负载GDNF的微球,可通过立体定向植入大脑,并可为帕金森病的治疗提供一种替代策略。采用水包油包水萃取-蒸发技术制备负载蛋白质的微球。需要对蛋白质进行体外释放研究,以评估微球制剂在持续释放方面的完整性保持情况和性能。为了评估负载GDNF的微球的体外释放曲线,进行了一项初步研究,使用实验设计选择一种合适的缓冲液来稳定GDNF。通过酶联免疫吸附测定(ELISA)和使用(125)I-GDNF的放射性测量来测定GDNF。在低连续流系统中评估负载GDNF的微球的释放曲线,结果显示在临床相关剂量下,生物活性GDNF在56天内持续释放。